Latest Eastern Cooperative Oncology Group Stories
Entinostat is being investigated in patients with advanced hormone receptor-positive breast cancer by the ECOG-ACRIN Cancer Research Group in its latest trial, E2112. Philadelphia,
Allegheny Health Network Cancer Institute has earned QOPI® (Quality Oncology Practice Initiative) Certification for its commitment to achieving excellence and ongoing quality improvement
WALTHAM, Mass., Feb.
New Members Contribute Expertise and Vision to LUNGevity's Research Program WASHINGTON, Feb.
Ibrutinib, a small molecule inhibitor of Bruton’s tyrosine kinase, will be investigated in combination with rituximab by the ECOG-ACRIN Cancer Research Group in its latest clinical trial, E1912.
WALTHAM, Mass., Feb. 3, 2014 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., today announced the appointment of distinguished breast cancer specialist, George W.
Blinatumomab, the first BiTE® antibody to be developed for the treatment of cancer, is being investigated by the ECOG-ACRIN Cancer Research Group in its latest trial, E1910. Philadelphia,
An analysis by ECOG-ACRIN researchers shows that TILs are a prognostic factor in women with triple negative breast cancer. San Antonio, TX (PRWEB) December 13,
Results from an ECOG-ACRIN Cancer Research Group trial show the benefit of using the combination of docetaxel and ADT as initial treatment. Philadelphia, PA
18 percent of lung cancers detected by low-dose CT are indolent according to ECOG-ACRIN Cancer Research Group study. Philadelphia, PA (PRWEB) December 09, 2013
- totally perplexed and mixed up.